COMMUNIQUÉS West-GlobeNewswire

ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity
17/09/2019
PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
17/09/2019
BRISBANE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value [...]
Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise
17/09/2019
Global partnership spans Amgen’s entire portfolio of pipeline and marketed blood cancer therapies SEATTLE, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced it has [...]
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
17/09/2019
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
17/09/2019
NORCROSS, Ga., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have [...]
Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel
17/09/2019
SANTA MONICA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced [...]
Transactions in relation to share buyback program
17/09/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 1, 2019, in accordance with article 5 of Regulation (EU) no. 596/2014 of April 16, 2014 on [...]
Tauriga Sciences Inc. Commences Production of its Pomegranate Flavored Version of Tauri-Gum
17/09/2019
Tauri-Gum™ Product Line – Now Encompasses Three Dynamic Flavors! New York, NY, Sept. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue [...]
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th
17/09/2019
DUBLIN, Ireland, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that [...]
Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease
17/09/2019
First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease Follows Breakthrough Device designation for Virtue Sirolimus-Eluting Balloon [...]
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
17/09/2019
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the [...]
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
17/09/2019
Results expected in second half of 2020 SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, [...]
Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe
17/09/2019
Next-Generation Professional CGM Combines Valuable Data with Optimal User Experience DUBLIN, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, [...]
Demant A/S: Update on IT infrastructure incident
17/09/2019
Company announcement no 2019-10 17 September 2019 As previously announced, the Demant Group experienced a critical incident in our internal IT infrastructure on 3 September 2019 when the Group’s IT infrastructure was [...]
CMR Surgical raises £195 million ($240 million) in Series C financing
17/09/2019
CMR Surgical Limited ("CMR Surgical" or the "Company") CMR Surgical raises £195 million ($240 million) in Series C financing ~ Europe’s largest private financing round in the medical technology sector ~ Financing will [...]
Nicox: First Half 2019 Financial Results and Business Update
17/09/2019
Press Release Nicox: First Half 2019 Financial Results and Business Update H1 2019 net revenue 1 of €5.6 million and net loss 2 of €0.8 million Enrollment completed in NCX 470 Phase 2 DOLOMITES clinical trial in [...]
Nicox : Résultats financiers du premier semestre 2019 et point des activités
17/09/2019
Communiqué de presse Nicox : Résultats financiers du premier semestre 2019 et point des activités Chiffre d’affaires net 1 pour le premier semestre 2019 de 5,6 millions d’euros et perte nette 2 de 0,8 million d’euros [...]
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
17/09/2019
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has submitted to EMA for [...]
Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses
17/09/2019
Pratteln, Switzerland, September 17, 2019 – Santhera Pharmaceuticals (SIX: SANN) will present data on the therapeutic effects of long-term treatment with Puldysa® (idebenone) in Duchenne muscular dystrophy (DMD) at the [...]

Pages